EP860 Redox Status of the Blood of Patients with Ovarian Cancer with Different Prevalence and Course of the Disease

Introduction/Background A comparative analysis of the intensity of oxidative processes and the activity of antioxidant enzymes in the blood of patients with ovarian cancer (OC) was carried out, depending on the prevalence of process and the presence of recurrence. Methodology The intensity of lipid peroxidation (LPO), the activity of superoxide dismutase, catalase, glutathione system and ceruloplasmin (main antioxidant protein of blood plasma), levels of proteins of the acute inflammation phase - C-reactive protein (CRP) and haptoglobin were studied in the blood of 114 OC patients. The data were analyzed using Statistika 6.0 programs, Student´s t-test and Mann-Whitney U test. Results Ascitic OC was characterized by a high intensity of free radical units of LPO and the maximal increase in CRP and haptoglobin levels (respectively by 17.5 and 2.2 times, compared to stage I-II OC). Patients with advanced OC without ascites showed significantly lower intensity of chemiluminescence (CL) reflecting the formation of free radicals, and higher levels of the molecular product, malondialdehyde (MDA), in the blood plasma compared to patients with ascites (p<0.02). The disease recurrence was accompanied by increased CL by 3 times and MDA level in erythrocytes by 43%, compared to non-cancer women. The key role in the utilization of hydrogen peroxide went from catalase to glutathion peroxidase (GPO), as evidenced by an increase in the GPO/catalase ratio in erythrocytes by 2.6–2.8 times, while in patients with primary OC such changes were not observed. Only patients with stage I–II OC showed all the coefficients reflecting the ratio of activity of antioxidant enzymes similar to the values in healthy women. Conclusion The revealed features of the intensity of oxidative processes and balance of activity of antioxidant enzymes in patients with ovarian cancer can contribute to the understanding of disease progression conditions and mechanisms that mediate the effectiveness of antitumor treatment. Disclosure Nothing to disclose.